Italian cohort of patients affected by inflammatory bowel disease is characterised by variation in glycerophospholipid, free fatty acids and amino acid levels.
Santoru, Maria Laura
MetadataShow full item record
Murgia, A., Hinz, C., Liggi, S., Denes, J., Hall, Z., West, J., Santoru, M. L., et al. (2018). Italian cohort of patients affected by inflammatory bowel disease is characterised by variation in glycerophospholipid, free fatty acids and amino acid levels.. Metabolomics, 14 (10. 140) https://doi.org/10.1007/s11306-018-1439-4
BACKGROUND: Inflammatory bowel disease is a group of pathologies characterised by chronic inflammation of the intestine and an unclear aetiology. Its main manifestations are Crohn's disease and ulcerative colitis. Currently, biopsies are the most used diagnostic tests for these diseases and metabolomics could represent a less invasive approach to identify biomarkers of disease presence and progression. OBJECTIVES: The lipid and the polar metabolite profile of plasma samples of patients affected by inflammatory bowel disease have been compared with healthy individuals with the aim to find their metabolomic differences. Also, a selected sub-set of samples was analysed following solid phase extraction to further characterise differences between pathological samples. METHODS: A total of 200 plasma samples were analysed using drift tube ion mobility coupled with time of flight mass spectrometry and liquid chromatography for the lipid metabolite profile analysis, while liquid chromatography coupled with triple quadrupole mass spectrometry was used for the polar metabolite profile analysis. RESULTS: Variations in the lipid profile between inflammatory bowel disease and healthy individuals were highlighted. Phosphatidylcholines, lyso-phosphatidylcholines and fatty acids were significantly changed among pathological samples suggesting changes in phospholipase A2 and arachidonic acid metabolic pathways. Variations in the levels of cholesteryl esters and glycerophospholipids were also found. Furthermore, a decrease in amino acids levels suggests mucosal damage in inflammatory bowel disease. CONCLUSIONS: Given good statistical results and predictive power of the model produced in our study, metabolomics can be considered as a valid tool to investigate inflammatory bowel disease.
CCS, Crohn’s disease, IBD, Lipidomics, Metabolomics, Ulcerative colitis
This study was funded by Agilent Technologies, Regione Autonoma della Sardegna (L.R.7/2007, Grant Number F71J12001180002), and the Medical Research Council UK (Grant Number MR/P011705/1).
Medical Research Council (MR/P011705/1)
Medical Research Council (MR/P01836X/1)
Medical Research Council (MC_PC_13030)
External DOI: https://doi.org/10.1007/s11306-018-1439-4
This record's URL: https://www.repository.cam.ac.uk/handle/1810/291143